Carsten Grüllich

Carsten Grüllich

Auto-generated profile, based on publicly available information

Carsten Grüllich

Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 June 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
RHRouven Hoefflin
Rouven Hoefflin
BLBernd Lahrmann
Bernd Lahrmann
GWGregor Warsow
Gregor Warsow
DHDaniel Hübschmann
Daniel Hübschmann
CSCathleen Spath
Cathleen Spath
SDStefan Duensing
Stefan Duensing
Intratumoural heterogeneity (ITH) is a major cause of cancer-associated lethality. Extensive genomic ITH has previously been reported in clear cell renal cell carcinoma (ccRCC). Here we address the question whether ITH increases with malignant progression and can hence be exploited as a prognostic marker. Unexpectedly, precision quantitative image analysis reveals that the degree of functional ITH is virtually identical between primary ccRCCs of the lowest stage and advanced, metastatic tumours. Functional ITH was found to show a stage-independent topological pattern with peak proliferative and signalling activities almost exclusively in the tumour periphery. Exome sequencing of matching peripheral and central primary tumour specimens reveals various region-specific mutations. However, these mutations cannot directly explain the zonal pattern suggesting a role of microenvironmental factors in shaping functional ITH. In conclusion, our results indicate that ITH is an early and general characteristic of malignant growth rather than a consequence of malignant progression.

2 August 2018
Verified
Book Chapter
Closed access
PDF file
SZStefanie Zschäbitz
Stefanie Zschäbitz
CGCarsten Grüllich
Carsten Grüllich

26 January 2001 in FEBS Letters
Verified
Journal Article
Closed access
CGCarsten Grüllich
Carsten Grüllich
RDRobert M. Duvoisin
Robert M. Duvoisin
MWMartin Wiedmann
Martin Wiedmann
KLKlaus van Leyen
Klaus van Leyen

1 March 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CGCarsten Grullich
Carsten Grullich
MSM.CAmeron Sullards
M.CAmeron Sullards
ZFZvi Fuks
Zvi Fuks
AMAlfred H. Merrill
Alfred H. Merrill
RKRichard Kolesnick
Richard Kolesnick
Although numerous studies document caspase-independent ceramide generation preceding apoptosis upon environmental stress, the molecular ordering of ceramide generation during cytokine-induced apoptosis remains uncertain. Here, we show that CD95-induced ceramide elevation occurs during the initiation phase of apoptosis. We titrated down the amount of FADD transfected into HeLa and 293T cells until it was insufficient for apoptosis, although cycloheximide (CHX) still triggered the effector phase. Even in the absence of CHX, ceramide levels increased rapidly, peaking at 2.7 +/- 0.2-fold of control 8 h post-transfection. Dominant negative FADD failed to confer ceramide generation or CHX-mediated apoptosis. Ceramide generation induced by FADD was initiator caspase-dependent, being blocked by crmA. Limited pro-caspase 8 overexpression also increased ceramide levels 2.7 +/- 0.2-fold, yet failed, without CHX, to initiate apoptosis. Expression of membrane-targeted oligomerized CD-8 caspase 8 induced apoptosis without CHX, yet elevated ceramide only to a level equivalent to limited pro-caspase 8 transfection. Ceramide elevations were detected concurrently by diacylglycerol kinase and electrospray tandem mass spectrometry. These investigations provide evidence that ceramide generation is initiator caspase-dependent and occurs prior to commitment to the effector phase of apoptosis, definitively ordering ceramide as proximal in CD95 signaling.